Microlipoinjection for the elevation of depressed full-thickness skin grafts on the nose.
Hambley RM., Carruthers JA.
Case Report / Series, published in J Dermatol Surg Oncol (1992) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Case Report / Series
- Journal
- J Dermatol Surg Oncol (1992)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 1430553
- DOI
- 10.1111/j.1524-4725.1992.tb02768.x
Abstract (original English)
Full-thickness skin grafts on the dorsum of the nose may heal depressed and might benefit from elevation. Microlipoinjection has been used to elevate depressed tissue; however, the long-term persistence of the augmentation is questioned. To determine whether microlipoinjection beneath depressed full-thickness grafts on the dorsum of the nose can provide effective and persistent graft elevation. Microlipoinjection was performed at one to three sessions under depressed full-thickness skin grafts on the nose of four patients. Their appearance was assessed clinically and photographically for the amount of correction at their last postmicrolipoinjection visit. All four patients had clinically significant elevation of their full-thickness skin graft. In the two patients followed for over 3 years, significant augmentation persisted. Microlipoinjection can provide cosmetically useful soft tissue augmentation under depressed full-thickness skin grafts; this augmentation can persist.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • Without an adequate control group, treatment effects cannot be separated from other factors.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.